High Tide Reports Second Quarter 2026 Financial Results Featuring Record Revenue of $179.3MM, and Adjusted EBITDA of $13.9MM
Accessibility StatementSkip Navigation
The Company Also Reports Positive Free Cash Flow and Net Income
The Company’s German Medical Cannabis Subsidiary, Remexian Pharma GmbH (Remexian) Generated Re…